Outcome of Board Meeting held on May 29, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemo Pharma Laboratories Limited's board, at its May 29, 2025 meeting, approved the audited standalone financial results for Q4 and full year ended March 31, 2025. The statutory auditor issued an unmodified (unqualified) opinion, but flagged an Emphasis of Matter regarding a Rs 2.20 crore inter-corporate deposit given to M/s Solding Hydrowatt Private Limited (a related party) at interest rates that may not be at arm's length, resulting in under-reported interest income. Full-year FY25 profit after tax stood at Rs 34.22 lakh, down roughly 72% from Rs 1.20 crore in FY24, with Q4 FY25 alone posting a loss of Rs 33.96 lakh. Other income collapsed from Rs 1.84 crore (FY24) to Rs 62 lakh (FY25), and operating cash flow turned negative at Rs (28.25) lakh versus Rs 72.36 lakh positive last year. Notably, 100% of the company's loans and advances (Rs 2.5 crore) are extended to related parties.
Mixed-to-negative for shareholders — while the audit opinion remains clean, the sharp earnings fall, auditor-flagged related-party lending at non-arm's length rates, and negative operating cash flow raise concerns about business momentum and governance quality.